The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Beta Bionics Inc’s stock clocked out at $29.38, down -2.07% from its previous closing price of $30.0. In other words, the price has decreased by -$2.07 from its previous closing price. On the day, 0.93 million shares were traded. BBNX stock price reached its highest trading level at $30.925 during the session, while it also had its lowest trading level at $28.76.
Ratios:
To gain a deeper understanding of BBNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 10.64. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 01, 2025, Goldman Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $26.
On June 16, 2025, Truist started tracking the stock assigning a Buy rating and target price of $26.Truist initiated its Buy rating on June 16, 2025, with a $26 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Mark Hopman bought 2,061 shares for $30.66 per share.
Mensinger Mike sold 1,063 shares of BBNX for $31,184 on Dec 02 ’25. The Chief Product Officer now owns 90,752 shares after completing the transaction at $29.34 per share. On Dec 02 ’25, another insider, Feider Stephen, who serves as the Chief Financial Officer of the company, sold 1,427 shares for $29.34 each. As a result, the insider received 41,862 and left with 42,614 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 1293443712 and an Enterprise Value of 1072443648. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.60 while its Price-to-Book (P/B) ratio in mrq is 4.38. Its current Enterprise Value per Revenue stands at 12.108 whereas that against EBITDA is -15.929.
Stock Price History:
Over the past 52 weeks, BBNX has reached a high of $32.71, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is 16.95%, while the 200-Day Moving Average is calculated to be 61.25%.
Shares Statistics:
It appears that BBNX traded 816.48K shares on average per day over the past three months and 771550 shares per day over the past ten days. A total of 43.99M shares are outstanding, with a floating share count of 33.42M. Insiders hold about 24.10% of the company’s shares, while institutions hold 94.81% stake in the company. Shares short for BBNX as of 1763078400 were 3572312 with a Short Ratio of 4.38, compared to 1760486400 on 4169413. Therefore, it implies a Short% of Shares Outstanding of 3572312 and a Short% of Float of 9.15.
Earnings Estimates
A detailed examination of Beta Bionics Inc (BBNX) is currently in progress, with 6.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.34 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.64 and -$2.06 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.66, with 6.0 analysts recommending between -$1.27 and -$2.0.
Revenue Estimates
In. The current quarter, 10 analysts expect revenue to total $28.9M. It ranges from a high estimate of $29.8M to a low estimate of $28M. As of. The current estimate, Beta Bionics Inc’s year-ago sales were $20.44MFor the next quarter, 10 analysts are estimating revenue of $27.55M. There is a high estimate of $30.67M for the next quarter, whereas the lowest estimate is $24.2M.
A total of 10 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $97.9M, while the lowest revenue estimate was $96.5M, resulting in an average revenue estimate of $97.13M. In the same quarter a year ago, actual revenue was $65.12MBased on 10 analysts’ estimates, the company’s revenue will be $132.25M in the next fiscal year. The high estimate is $143.98M and the low estimate is $121M.
